Beyond the Vial: How the Cell and Gene Therapy CDMO Market Is Redefining Advanced Medicine Manufacturing

Cell and gene therapies have captured the imagination of clinicians, investors, and patients alike — but behind every approved CAR-T infusion or gene-corrected stem cell product lies an intricate manufacturing story that rarely makes headlines. Contract development and manufacturing organizations (CDMOs) are the industrial backbone of this revolution, providing the specialized facilities, process expertise, and regulatory know-how that most therapy developers cannot economically build on their own. Understanding who controls that backbone — and how it is evolving — matters enormously for sponsors, investors, and healthcare systems planning for a future shaped by personalized medicine.

Nexvora Intelligence estimates the global cell and gene therapy CDMO market at approximately $7.8 to $8.6 billion in 2025. That figure, while already substantial, understates the strategic weight of the sector. Late-stage and commercial manufacturing programs — where batch failures carry catastrophic commercial consequences — are claiming a growing share of that revenue, shifting the CDMO relationship from a transactional service arrangement to a mission-critical partnership. The implication for sponsors is clear: CDMO selection has become a board-level risk management decision, not merely a procurement exercise.

Nexvora's modeled projections place the global cell and gene therapy CDMO market on a growth trajectory of 17% to 21% compound annual growth rate from 2025 through 2032, reaching an estimated $24 to $31 billion by the end of the forecast period. This range reflects genuine uncertainty in the pace of regulatory approvals, the speed at which allogeneic platforms achieve scalable manufacturing, and the degree to which reimbursement frameworks in major markets will sustain commercial demand. Even the conservative end of this range, however, represents a market roughly tripling in size within seven years — an extraordinary expansion by any industrial measure.

The tailwinds driving this growth are structural rather than cyclical. Global clinical pipelines in cell and gene therapy have deepened considerably, with programs spanning oncology, rare genetic diseases, ophthalmology, and cardiovascular indications now at late-stage development or early commercial launch. Each approved product anchors a long-term supply relationship with its manufacturing partner. As the cumulative number of commercial-stage therapies grows, the base of recurring, high-value CDMO revenue expands accordingly. Nexvora's assessment is that this compounding effect — approvals begetting multi-year supply agreements, which in turn fund CDMO capacity that attracts additional early-stage clients — is the fundamental engine of market growth through 2032.

No service category inside the cell and gene therapy CDMO ecosystem carries more strategic weight than viral vector manufacturing. Nexvora estimates that viral vector services — spanning plasmid DNA supply, upstream process development, GMP production of adeno-associated virus (AAV), lentiviral vectors (LVV), and related modalities, plus the deep analytical testing needed to characterize them — represent roughly 35% to 42% of total 2025 market value. That concentration reflects the biological reality that most approved and late-stage gene therapies depend on viral delivery systems whose manufacture is genuinely difficult, reproducible only with significant process knowledge, and validated against rigorous regulatory expectations.

The strategic constraint in viral vectors is not simply about physical capacity. Titer variability, empty/full capsid ratios, residual host cell protein levels, and batch-to-batch consistency define whether a CDMO partner can meet release specifications reliably. Sponsors advancing into pivotal trials or commercial launch cannot afford a single failed batch that delays product availability for patients on a waiting list. This reality has made viral vector CDMOs with proven batch reliability and deep analytical capability the most competitively insulated participants in the market. Nexvora's assessment is that pricing for qualified, late-stage viral vector manufacturing will remain resilient even as overall CDMO capacity grows, because the barrier to entry is less about hardware than about accumulated process understanding and regulatory history.

While gene therapy manufacturing headlines often focus on viral vectors, the cell therapy manufacturing segment is undergoing its own quiet transformation. Early clinical programs frequently relied on manual, open-processing workflows adapted from academic laboratory practice — approaches that are inherently difficult to scale, validate, and reproduce across geographies. As autologous CAR-T therapies transition from early-stage novelties to commercially established treatments, and as allogeneic platforms promise to reduce per-patient manufacturing complexity, the entire sector is migrating toward semi-automated, closed-system workflows that can be validated, transferred, and quality-controlled with the rigor that commercial manufacturing demands.

CDMOs that invested early in closed-system bioprocessing equipment, automated cell expansion platforms, and cryopreservation capabilities are now capturing a disproportionate share of late-stage and commercial cell therapy programs. Next-generation immune cell therapies — including NK cell, gamma-delta T cell, and tumor-infiltrating lymphocyte (TIL) products — are adding further complexity and opportunity to the service portfolio. Nexvora's modeled view is that CDMOs capable of supporting multiple cell therapy modalities within a single integrated platform will command premium positioning, as sponsors value the reduction in technology transfer risk and regulatory complexity that comes from working with a single qualified partner across a diversified pipeline.

A defining strategic trend in this market is the growing preference among therapy sponsors for integrated CDMO partners capable of supporting the full manufacturing value chain — from upstream plasmid DNA and viral vector production through cell processing, analytical development, quality release testing, regulatory documentation, and fill-finish. The logic is straightforward: each handoff between separate specialist contractors introduces interface risk, timeline uncertainty, and potential regulatory complications at comparability boundaries. As therapies advance toward commercial launch, the cost of those interface risks becomes prohibitive.

Integrated CDMOs have responded by expanding their service breadth through organic investment and strategic acquisition. The result is a bifurcating competitive landscape: a small number of large, vertically integrated organizations capable of end-to-end program support, alongside a larger population of specialist CDMOs that compete on depth of expertise in a particular modality or process step. Nexvora's assessment is that this bifurcation will persist through 2032, with integrated players capturing commercial and pivotal-stage programs while specialists retain relevance for early-stage development, niche modalities, and programs where a sponsor has strong internal capabilities in adjacent areas. Sponsors who understand this landscape will make more deliberate partnership decisions rather than defaulting to the largest available provider.

North America commands the largest share of global cell and gene therapy CDMO revenue, which Nexvora estimates at roughly 45% to 50% of 2025 market value. This leadership reflects the concentration of therapy sponsors, regulatory maturity of the FDA's advanced therapy frameworks, proximity to major clinical research infrastructure, and the depth of specialized workforce available in biotech hubs along the eastern seaboard and in California. The United States in particular has benefited from a regulatory environment that, while demanding, has developed relatively predictable pathways for cell and gene therapy approval — providing sponsors and their CDMO partners with clearer targets for process validation and documentation.

Europe holds a meaningful second position, supported by EMA's Advanced Therapy Medicinal Products (ATMP) regulatory framework and a strong base of both academic research and established pharmaceutical manufacturing expertise in countries including the United Kingdom, Germany, and Switzerland. Asia-Pacific, however, is where Nexvora models the fastest growth through 2032. Expanding domestic biotech pipelines in South Korea, Japan, and China — combined with government investment in advanced therapy manufacturing infrastructure and a growing appetite from Western sponsors to diversify supply chains — are positioning Asia-Pacific CDMOs for accelerating revenue growth. Sponsors assessing geographic supply risk should treat Asia-Pacific CDMO capability development as a material factor in long-term manufacturing strategy, not merely a cost arbitrage opportunity.

The CDMO competitive landscape is experiencing a notable divergence in pricing dynamics depending on program stage. For complex, late-stage, and commercial-ready manufacturing programs — where validated processes, regulatory history, and batch reliability are non-negotiable requirements — pricing has remained resilient. The number of CDMOs genuinely qualified to support a pivotal or commercial program is limited, and sponsors are willing to pay for certainty. In contrast, early-stage process development capacity has become meaningfully more competitive as facility expansions completed over the past several years have increased supply without a proportional increase in early-stage program volume. Sponsors are now scrutinizing cost and capital efficiency more carefully in pre-IND and Phase I program scoping.

This divergence has significant strategic implications for CDMOs across the competitive spectrum. For established players, the premium pricing environment at late-stage is an incentive to maintain the highest standards of batch reliability and regulatory preparedness, because slipping from that tier is far more costly than any short-term efficiency gain. For emerging CDMOs, the more competitive early-stage environment demands a clear articulation of specialized capability — whether in a particular vector serotype, a specific cell type, a proprietary analytical platform, or an unusually rapid technology transfer methodology. Generic claims of 'state-of-the-art facilities' will not sustain positioning in a market where sponsors have more early-stage options and are asking harder questions about differentiation.

Nexvora's analysis of competitive positioning across the cell and gene therapy CDMO market identifies five differentiation variables that will increasingly separate market leaders from the field through 2032. First, batch reliability — the consistent ability to manufacture to specification and release product on schedule — will remain the foundational metric by which sponsors evaluate existing relationships and select new partners. No amount of facility investment compensates for a track record of out-of-specification batches or unexplained process variability. Second, regulatory maturity, meaning an organization's institutional knowledge of how to generate, structure, and defend the documentation that supports IND submissions, BLA filings, and post-approval lifecycle management, will grow in importance as more programs reach pivotal and commercial stages.

Third, assay depth and analytical development capability will increasingly define commercial readiness. The ability to develop, qualify, and transfer potency assays, vector genome titer methods, and cell characterization panels — and to defend those methods under regulatory scrutiny — is a genuine source of competitive advantage. Fourth, technology transfer execution quality will matter more as sponsors seek to bring commercial manufacturing to multiple sites for supply resilience. CDMOs that can transfer processes cleanly, quickly, and with minimal comparability risk will command preference. Fifth, and perhaps most forward-looking, the ability to support lifecycle changes — including process improvements, raw material substitutions, and manufacturing scale adjustments — without compromising comparability or triggering major regulatory variations will become a defining differentiator as commercial programs mature. Sponsors and investors evaluating CDMO partners should weight these operational dimensions at least as heavily as facility scale and geography.